Menu
Search
|

Menu

Close
X

Prana Biotechnology Ltd PRAN.OQ (NASDAQ Stock Exchange Capital Market)

2.94 USD
+0.05 (+1.73%)
As of Feb 16
chart
Previous Close 2.89
Open 2.90
Volume 1,431
3m Avg Volume 11,677
Today’s High 2.96
Today’s Low 2.90
52 Week High 4.57
52 Week Low 2.05
Shares Outstanding (mil) 8.90
Market Capitalization (mil) 24.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, AUD)
FY17
0
FY16
0
FY15
0
EPS (AUD)
FY17
-0.085
FY16
-0.060
FY15
-0.069
*Note: Units in Millions of Australian Dollars
**Note: Units in Australian Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
241.96
5.77
Price to Book (MRQ)
vs sector
0.21
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-27.40
14.43
Return on Equity (TTM)
vs sector
-27.40
16.13

EXECUTIVE LEADERSHIP

Geoffrey Kempler
Executive Chairman of the Board, Chief Executive Officer, Since 2005
Salary: $419,313.00
Bonus: --
Kathryn Andrews
Chief Financial Officer, Since 2014
Salary: $131,826.00
Bonus: --
Dianne Angus
Chief Operating Officer, Since 2007
Salary: $328,799.00
Bonus: --
David Stamler
Chief Medical Officer and Senior Vice President Clinical Development, Since 2017
Salary: --
Bonus: --
Phillip Hains
Company Secretary, Since 2014
Salary: $100,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

PO Box 655
MELBOURNE   VIC   3053

Phone: +613.93494906

Prana Biotechnology Limited is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

SPONSORED STORIES